Supplementary Material for: Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery

<b><i>Introduction:</i></b> The aim of this study was to identify preoperative risk factors for poor survival in patients with resectable pancreatic ductal adenocarcinoma (PDAC) treated with upfront surgery. <b><i>Methods:</i></b> Medical records of 268 patients with resectable PDAC defined by resectability status who underwent upfront surgery were reviewed retrospectively. Multivariate analyses were performed to identify preoperative risk factors for recurrence-free survival (RFS) and overall survival (OS). Moreover, a binary logistic regression model was built to determine preoperative independent risk factors of 2- and 3-year recurrence and survival. <b><i>Results:</i></b> Multivariate analyses identified CA19-9 (≥100 U/mL, <i>p</i> &lt; 0.001) as an independent risk factor for poor RFS, and worse performance status (1 or 2, <i>p</i> = 0.03), platelet:lymphocyte ratio (&lt;150, <i>p</i> = 0.04), and preoperative CA19-9 (≥100 U/mL, <i>p</i> &lt; 0.001) as independent risk factors for poor OS. Moreover, preoperative CA19-9 (≥100 U/mL) was the only independent risk factor identified for 2- and 3-year recurrence and survival. <b><i>Discussion/Conclusion:</i></b> Preoperative CA19-9 (≥100 U/mL) was the most reliable preoperative predictive factor for poor survival in resectable PDAC treated with upfront surgery. These findings warrant further clinical trials investigating efficacy of neoadjuvant therapy targeting the subset of patients with resectable PDAC who have elevated preoperative CA19-9, namely, those with high risk of poor prognosis.